Pharming licenses orphan drug from Novartis

Novartis AG’s small molecule phosphoinositide 3-kinase delta (PI3Kẟ) blocker CDZ173, which is in a registration-enabling study, is expected to reach the market in 2022 lastest. Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is an ultra-rare, debilitating...